Your browser doesn't support javascript.
loading
Correlating chemical sensitivity and basal gene expression reveals mechanism of action.
Rees, Matthew G; Seashore-Ludlow, Brinton; Cheah, Jaime H; Adams, Drew J; Price, Edmund V; Gill, Shubhroz; Javaid, Sarah; Coletti, Matthew E; Jones, Victor L; Bodycombe, Nicole E; Soule, Christian K; Alexander, Benjamin; Li, Ava; Montgomery, Philip; Kotz, Joanne D; Hon, C Suk-Yee; Munoz, Benito; Liefeld, Ted; Dancík, Vlado; Haber, Daniel A; Clish, Clary B; Bittker, Joshua A; Palmer, Michelle; Wagner, Bridget K; Clemons, Paul A; Shamji, Alykhan F; Schreiber, Stuart L.
Afiliação
  • Rees MG; Broad Institute, Cambridge, Massachusetts, USA.
  • Seashore-Ludlow B; Broad Institute, Cambridge, Massachusetts, USA.
  • Cheah JH; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Adams DJ; Broad Institute, Cambridge, Massachusetts, USA.
  • Price EV; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Gill S; Broad Institute, Cambridge, Massachusetts, USA.
  • Javaid S; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Coletti ME; Broad Institute, Cambridge, Massachusetts, USA.
  • Jones VL; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Bodycombe NE; Broad Institute, Cambridge, Massachusetts, USA.
  • Soule CK; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, USA.
  • Alexander B; Broad Institute, Cambridge, Massachusetts, USA.
  • Li A; Broad Institute, Cambridge, Massachusetts, USA.
  • Montgomery P; Broad Institute, Cambridge, Massachusetts, USA.
  • Kotz JD; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Hon CS; Broad Institute, Cambridge, Massachusetts, USA.
  • Munoz B; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Liefeld T; Broad Institute, Cambridge, Massachusetts, USA.
  • Dancík V; Broad Institute, Cambridge, Massachusetts, USA.
  • Haber DA; Broad Institute, Cambridge, Massachusetts, USA.
  • Clish CB; Broad Institute, Cambridge, Massachusetts, USA.
  • Bittker JA; Broad Institute, Cambridge, Massachusetts, USA.
  • Palmer M; Broad Institute, Cambridge, Massachusetts, USA.
  • Wagner BK; Broad Institute, Cambridge, Massachusetts, USA.
  • Clemons PA; Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (B.S.L); Koch Institute for Cancer Research at MIT, Cambridge, Massachusetts, US
  • Shamji AF; Broad Institute, Cambridge, Massachusetts, USA.
  • Schreiber SL; Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, USA.
Nat Chem Biol ; 12(2): 109-16, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26656090
ABSTRACT
Changes in cellular gene expression in response to small-molecule or genetic perturbations have yielded signatures that can connect unknown mechanisms of action (MoA) to ones previously established. We hypothesized that differential basal gene expression could be correlated with patterns of small-molecule sensitivity across many cell lines to illuminate the actions of compounds whose MoA are unknown. To test this idea, we correlated the sensitivity patterns of 481 compounds with ∼19,000 basal transcript levels across 823 different human cancer cell lines and identified selective outlier transcripts. This process yielded many novel mechanistic insights, including the identification of activation mechanisms, cellular transporters and direct protein targets. We found that ML239, originally identified in a phenotypic screen for selective cytotoxicity in breast cancer stem-like cells, most likely acts through activation of fatty acid desaturase 2 (FADS2). These data and analytical tools are available to the research community through the Cancer Therapeutics Response Portal.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Bibliotecas de Moléculas Pequenas Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Bibliotecas de Moléculas Pequenas Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article